More than an improvement of glomerular hyperfiltration reducing nocturnal hypoxia in sleep apnea patients with C-PAP [31], it was demonstrated that C-PAP therapy in OSA subjects was associated with improved renal hemodynamics and the down-regulation of renal renin-angiotensin activity, suggesting a potential therapeutic benefit on kidney function [5]. The gene discussed is REN; the disease is obstructive sleep apnea syndrome.